Polymerase Chain Reaction (PCR)/Fluorescence Monitoring
- Use to support a clinical diagnosis of AD in symptomatic individuals
- Use for AD risk assessment only
- Genetic counseling and informed consent are strongly recommended both before ordering and posttest to discuss results.
Alzheimer's disease (AD) is the most common type of dementia, characterized by a progressive cognitive decline that affects aspects such as memory, problem-solving skills, multistep tasks, planning, and personality. Most individuals with AD have symptom onset at 60-65 years of age or later (termed late-onset AD), while only 5% of cases are early-onset (before 60-65 years of age). AD is a multifactorial condition, meaning multiple genetic and environmental factors may contribute to its development. It has been well established that the e4 allele of the APOE gene is more prevalent in individuals with AD, however, the presence of the e4 allele is neither required nor sufficient for a diagnosis. Identification of the e4 allele in an individual suspected to have AD can be used to support a suspected clinical diagnosis.
Disease Overview
Diagnosis
- Clinical diagnosis of AD is typically suspected based on symptoms of slowly progressive dementia, neuroimaging findings of gross cerebral cortical atrophy, and exclusion of other causes of dementia.
- Additional studies that can support a clinical diagnosis of AD include amyloid positron emission tomography (PET) imaging and measurements of amyloid and tau in cerebral spinal fluid
- Confirmatory diagnostic testing for AD can only be performed postmortem, with the identification of hallmark neuropathologic findings such as beta (β)-amyloid plaques and intraneuronal neurofibrillary tangles containing tau protein.
- Many genes beyond APOE have been identified in association with late-onset AD, but their effect on disease risk is minimal. The clinical utility of testing for genetic factors to predict the risk of late-onset AD has not been established.
Incidence
Approximately 6.2 million Americans are currently living with AD, including about one in nine people over the age of 65.
Genetics
Gene Tested
APOE
Variants Tested
- e2 allele (cysteine at codons 130 and 176)
- e3 allele (cysteine at codon 130, arginine at codon 176)
- e4 allele (arginine at codons 130 and 176)
Inheritance
AD is a multifactorial condition. The e4 allele of APOE is semidominant with incomplete penetrance.
Prevalence
Test Interpretation
Analytical Sensitivity/Specificity
99%
Results
Finding | Significance |
---|---|
APOE e2/e2 |
Not associated with increased risk for AD, but has been associated with increased risk for type III hyperlipoproteinemia; does not exclude a diagnosis of AD |
APOE e2/e3 |
Not associated with increased risk for AD, but does not exclude a diagnosis of AD |
APOE e3/e3 |
Not associated with increased risk for AD, but does not exclude a diagnosis of AD |
APOE e2/e4 |
Adds support to a clinical diagnosis of AD in symptomatic individuals |
APOE e3/e4 |
Adds support to a clinical diagnosis of AD in symptomatic individuals |
APOE e4/e4 |
Adds substantial support to a clinical diagnosis of AD in symptomatic individuals |
Limitations
- The presence of one or more APOE e4 alleles is considered a risk factor but is not diagnostic for AD.
- Only the APOE alleles e2, e3, and e4 will be detected; other APOE alleles and variants in other genes associated with AD are not analyzed.
- Diagnostic errors can occur due to rare sequence variations.
References
-
GeneReviews - Alzheimer Disease Overview
Bird TD. Alzheimer disease overview. In: Adam MP, Feldman J, Mirzaa GM, et al, eds. GeneReviews. University of Washington, Seattle. Updated Dec 2018; accessed Aug 2024.
-
24849862
Dubois B, Feldman HH, Jacova C, et al. Advancing research diagnostic criteria for Alzheimer's disease: the IWG-2 criteria. Lancet Neurol. 2014;13(6):614-629.
-
22101365
Montine TJ, Phelps CH, Beach TG, et al. National Institute on Aging-Alzheimer's Association guidelines for the neuropathologic assessment of Alzheimer's disease: a practical approach. Acta Neuropathol. 2012;123(1):1-11.
-
26312828
Van Cauwenberghe C, Van Broeckhoven C, Sleegers K. The genetic landscape of Alzheimer disease: clinical implications and perspectives. Genet Med. 2016;18(5):421-430.
-
28898389
Rajan KB, Barnes LL, Wilson RS, et al. Racial differences in the association between apolipoprotein E risk alleles and overall and total cardiovascular mortality over 18 years. J Am Geriatr Soc. 2017;65(11):2425-2430.
-
22179327
Ward A, Crean S, Mercaldi CJ, et al. Prevalence of apolipoprotein E4 genotype and homozygotes (APOE e4/4) among patients diagnosed with Alzheimer's disease: a systematic review and meta-analysis. Neuroepidemiology. 2012;38(1):1-17.
Alzheimer's and dementia facts and figures
Alzheimer’s Association. Alzheimer’s and dementia facts and figures. Accessed: Oct 2021.